Insmed Incorporated (INSM)

Market Cap	18.90B
Revenue (ttm)	381.03M
Net Income (ttm)	-1.01B
Shares Out	189.95M
EPS (ttm)	-5.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,428,818
Open	101.67
Previous Close	101.74
Day's Range	98.85 - 102.25
52-Week Range	60.40 - 106.83
Beta	0.79
Analysts	Strong Buy
Price Target	106.80 (+7.35%)
Earnings Date	Aug 7, 2025

About INSM

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2000
• Employees: 1,271
• Stock Exchange: NASDAQ
• Ticker Symbol: INSM
• Website: https://www.insmed.com

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Analyst Forecast

According to 17 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $106.8, which is an increase of 7.35% from the latest price.

Price Target

$106.8

(7.35% upside)

Analyst Consensus: Strong Buy